$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Chronic kidney disease (CKD) is a progressive condition that affects a significant portion of the global population. It is characterized by the gradual loss of endocrine and filtrative kidney function over time, leading to the accumulation of waste products and fluid in the body and an imbalance in the endocrine system. Recent data suggest that 9.1% to 13.4% of the worldwide population (between 700 million and one billion people) has CKD1. The prevalence of CKD increases with age, affecting around 34% of people aged 65 years or older in the United States, compared to 12% in those aged 45-64 years and 6% in those aged 18-44 years2.
Therefore, CKD is a significant contributor to the global burden of disease and mortality rates. Early detection and management of CKD are crucial in slowing its progression and reducing the risk of complications, such as cardiovascular disease, anemia, and ultimately, end-stage renal disease, which requires dialysis or kidney transplantation for survival3.
Therapeutic interventions for end-stage CKD have undergone a remarkable evolution over the past few decades. Historically, the management of end-stage CKD was limited to supportive care, with dialysis emerging as a life-sustaining modality in the 1960s. Since then, significant advancements have been made in dialysis techniques, including the development of more biocompatible membranes, improved vascular access, and the advent of peritoneal dialysis4. Additionally, kidney transplantation has emerged as the optimal treatment for end-stage CKD, offering improved survival and quality of life compared to dialysis5. However, the shortage of donor organs remains a significant challenge, driving research into novel strategies such as xenotransplantation and regenerative medicine approaches. Furthermore, the management of end-stage CKD-associated complications, such as secondary hyperparathyroidism, has been enhanced by the introduction of calcimimetic agents like etelcalcetide, which effectively modulate parathyroid hormone levels6.
Despite these advancements, the quest for more effective and targeted therapies continues, fueled by ongoing research into the molecular mechanisms underlying end-stage CKD progression and associated comorbidities. Therefore, CKD persists as a significant concern in patient care, prompting a continued need for extensive research into biomedical processes and therapeutic approaches. Robust biological models are essential to facilitate such investigations. Given the multifaceted nature of CKD, which encompasses aspects ranging from cellular biology to interorgan endocrine signaling, vascular functional anatomy, and rheology, an ideal model must possess a level of biological complexity that only a comprehensive model organism can provide. Thus, rodents emerge as the preferred model due to their capacity to encompass these various biological dimensions effectively.
The 5/6 nephrectomy remnant kidney model serves as a common tool in CKD research for rat and murine experiments due to its stable induction of renal insufficiency7,8,9,10,11,12,13,14. This model entails the removal of one entire kidney and 2/3 of the other. The creation of the remnant kidney can be achieved through the surgical resection of renal poles, termed the polectomy model, or by ligating superior and inferior segmental renal arteries, resulting in pole infarction7,15,16,17,18,19,20.
While this 5/6 nephrectomy model with polectomy is an established technique, it has only been introduced as a transparent and comprehensible protocol with a dorsolateral retroperitoneal access21. This access can be advantageous for a unilateral procedure with renal parenchyma reduction on just one side or for a two-stage procedure with a temporal distance of a few days in order to increase postoperative survival of the animal22. However, the utilization of a midline laparotomy approach offers distinct advantages over the conventional laterodorsal retroperitoneal access route.
By employing a single midline abdominal incision, the surgeon gains unimpeded access to the entire abdominal cavity, thereby facilitating a comprehensive exploration and manipulation of the intra-abdominal organs. This expanded surgical field not only streamlines the nephrectomy procedure, but also enables the concurrent execution of additional interventions that may be required for specific experimental protocols, for example, procedures on the ureters, such as ligation, resection, or reconstruction, which may be essential for studying the pathophysiology of obstructive uropathy. Furthermore, this approach permits the simultaneous resection or manipulation of other abdominal organs, such as the liver, spleen, or gastrointestinal tract, thereby expanding the scope of experimental investigations into multi-organ interactions or systemic disease models.
Moreover, the midline laparotomy approach facilitates the construction of an ileum conduit or neobladder, a surgical procedure that involves the creation of a urinary diversion using a segment of the ileum, which is particularly relevant in studies investigating bladder dysfunction or reconstructive urology techniques. This versatility in combining nephrectomy with other surgical interventions within the same operative field not only streamlines experimental protocols but also minimizes cumulative surgical trauma and associated risks to the animal subjects. Therefore, in the case of single-stage bilateral renal surgery or simultaneous additional intraabdominal procedures, the ventral access via midline laparotomy should be the preferred option.
Currently, there is no publication or protocol available describing this surgical strategy. Therefore, with this work, our objective is to present a detailed procedural guide for conducting renal resection and surgical induction of CKD via midline laparotomy in rats, applicable to both survival and non-survival studies. This experimental model creates a regulated environment conducive to investigating the complex dynamics of CKD, mimicking clinically significant scenarios. This protocol was specifically designed to illustrate the surgical technique. The intervention was therefore performed in a non-survival setting on a homogeneous group of 10 male rats. As there was no meaningful reason for the comparison to a baseline or alternative intervention, the inclusion of a control group was not necessary. 5/6 nephrectomy explicitly refers to the extent of surgical parenchyma resection. This certainly translates to a functional reduction in the sense of a reduction of glomerular filtration rate. However, the exact functional degree cannot be predicted but will have to be measured individually for each animal, for example, by using inulin or p-aminohippuric acid clearance23,24 if required.